Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 8, Pages 1571-1578
Publisher
Springer Nature
Online
2013-04-12
DOI
10.1038/bjc.2013.145
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
- (2012) Zeeshan Butt et al. CANCER
- Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
- (2011) Eitan Amir et al. EUROPEAN JOURNAL OF CANCER
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
- (2011) J. L. Beaumont et al. ONCOLOGIST
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes
- (2009) David Cella CANCER TREATMENT REVIEWS
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib
- (2008) Peter C. Trask et al. ACTA ONCOLOGICA
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
- (2008) Kiran Gupta et al. CANCER TREATMENT REVIEWS
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
- (2008) T. Eisen et al. JNCI-Journal of the National Cancer Institute
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search